Vivo Capital, a California-China healthcare investment firm, has closed an early stage healthcare VC fund, the Vivo PANDA Fund, with more than $100 million. Traditionally, Vivo has looked for later-stage investments. In 2015, Vivo closed its $750 million eighth fund, which focused on China revenue-stage life science companies. The new fund will invest in innovative healthcare companies, including pharmaceuticals, biotechnology, medical devices and diagnostics, with an eye toward building cross-border partnerships. Vivo now manages over $1.8 billion.
